Ipca Laboratories Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9al055yk6eb60dmdig6a21a8.pdf

Key Takeaways


Margin Drivers: The Mix Effect

A.K. Jain: "See, gross margin this particular quarter was exceptionally high mainly because the overall, let's say, turnover in this quarter has grown by around 10%. Material cost, there is a significant reduction, against 10% growth, material cost has come down by around 5%. So that is the impact."

Unichem Turnaround

A.K. Jain: "And overall, it's basically improvement in operation that has got the results right now and a long way to go, I would say that, the margin will keep on improving as far as Unichem is concerned."

Generic Exports: Headwinds and Recoveries

A.K. Jain: "Let's say, I think second quarter was very bad. But third quarter onwards, the prices have again started improving there and business has started improving overall. And I think we have a lot of launches also in pipeline. So I think in U.K. numbers, we will see around 15% to 17% kind of overall growth in next financial year."

Domestic Formulations: Chronic Strength, Acute Stagnation

A.K. Jain: "Rheumatology portfolio, is last 10, 15 years, also, we have seen continuously it's growing 1.5x the market growth. And we don't foresee next 5 years also that growth rate can come down."

Subsidiaries & Capacity

Harish Kamath: "Except Pisgah and our associate company Krebs, other all companies are profitable as on date... So only Pisgah and Krebs are little cause of concern."

Guidance & Commitments

CommitmentSpecificsTimeline
Standalone EBITDA margin23% to 24% (raised from ~21%)FY25 full year
Consolidated EBITDA margin19.18% to 19.5% (raised from ~18%)FY25 full year
Q4 material cost ratioBroadly around 28% to 29%Q4 FY25
U.K. business growth15% to 17% overall growthFY26
API business growth8% to 10%Going forward
Promotional market business growth8% to 9%FY25 full year
Net debt (standalone)Practically nilFY26
Margin improvement100 to 150 bpsNext 3-4 years
R&D spendMove to ~4% of revenueNo date; directional
Domestic growth vs IPM1.5x IPM growthComing few years
Pisgah turnaroundProfitableCouple of quarters
New orthopedics/dentals divisionBreakevenFY26
New cardiology divisionLaunch with ~300 peopleFY26
ANDA filings (Ipca)5-6 per yearOngoing annually
Effective tax rate27% to 28%Ongoing

Key Metrics

MetricQ3 FY25
Standalone revenue growth~10% YoY
Domestic formulation growth~13% for the quarter
API business growth~12% for the quarter
Overall formulation business growth~6% for the quarter
Standalone EBITDA margin~24.25%, vs 18.52% in Q3 FY24, improvement of ~5.73 ppt
Standalone 9M EBITDA margin~23.14%, vs 19.55% in 9M FY24, improvement of ~3.59 ppt
Consolidated EBITDA margin~19.87%, vs 16.1% in Q3 FY24, improvement of ~3.77 ppt
Consolidated 9M EBITDA margin~19.18%, vs 17.34% in 9M FY24, improvement of ~1.84 ppt
Full-year standalone EBITDA margin guidance~23% to 24% (original guidance ~21%)
Full-year consolidated EBITDA margin guidance~19.18% to 19.5% (original guidance ~18%)
Standalone material cost ratio~27.62% in Q3, vs ~28.9% in Q1 and ~29.59% in Q2
9M material cost ratio28.73%, vs ~32% in 9M FY24, improvement of ~3.37 ppt
Unichem EBITDA margin~12%, vs ~5% in Q3 FY24
Domestic market share (MAT Dec '24)2.05%, up 11 bps from 1.95% at Dec '23
IQVIA-tracked domestic growth11.4%, vs IPM growth of ~7.4%
Chronic segment growth (IQVIA)~17.1%, vs IPM chronic growth of ~9.7%
Acute segment growth (IQVIA)8.7%, vs IPM acute growth of ~6%
Pain portfolio growth (9M FY25)~14%
Domestic portfolio internal growth (9M FY25)~12%
ROW market business growth~50% YoY, from ~₹104 cr in Q3 FY24
EU generics growth~14% to 15%
U.K. generics growth outlook (FY26)~15% to 17%
API business growth outlook8% to 10%
Promotional market business growth outlook (FY25)~8% to 9%
MR productivity per month (9M FY25)₹4,45,000, vs ~₹4,25,000 with 6,300 people in 9M FY24
MR count~6,700
Dewas capacity utilization~35% to 40%
Ipca standalone gross debt~₹900 cr
Ipca standalone cash~₹600 cr
Ipca standalone net debt~₹300 cr
Effective tax rate~27% to 28%
R&D spend (Ipca + Unichem combined)~3% to 3.25% of sales, likely to move to ~4%
Pain management share of domestic business~52%
South Africa business decline~₹75 cr to ₹80 cr decline in FY25 from ~₹120 cr annual run-rate
Iran business₹0, down from ~₹75 cr to ₹80 cr annually